Cronos Group Inc. (CRON)
Nasdaq · Medicinal Chemicals & Botanical Products · Manufacturing · CIK 1656472 · fiscal year ends in Dec
Closing price $3.37 on 29 Oct 2026; 52-week range $2.30 to $3.55.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $179.1M
- Revenue growth
- 37.5%
- Net income, last twelve months
- $70.0M
- Earnings per share
- $0.20
- Gross margin
- 45.9%
- Operating margin
- -1.4%
- Net margin
- 39.1%
- Free cash flow
- $49.8M
- Return on equity
- 6.5%
- Market value
- $1.2B
- Price to earnings
- 16.8x
- Cash
- $467.0M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 370.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $146.6M | -$17.4M | -$9.4M | -$0.02 | $149.0K | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $117.6M | -$76.5M | $41.1M | $0.11 | $6.4M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $87.2M | -$84.8M | -$74.0M | -$0.19 | -$45.3M | 10-K filed 29 Feb 2024 |
| FY2022 | 31 Dec 2022 | $86.7M | -$111.4M | -$168.7M | -$0.45 | -$92.4M | 10-K filed 28 Feb 2023 |
| FY2021 | 31 Dec 2021 | $64.6M | -$292.0M | -$396.1M | -$1.07 | -$164.8M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $53.0M | $32.1M | $0.09 |
| Q1 FY2026 | 31 Mar 2026 | $45.2M | $13.8M | $0.04 |
| Q4 FY2025 | 31 Dec 2025 | $44.5M | -$1.8M | $0.00 |
| Q3 FY2025 | 30 Sep 2025 | $36.3M | $26.0M | $0.07 |
| Q2 FY2025 | 30 Jun 2025 | $33.5M | -$39.7M | -$0.10 |
| Q1 FY2025 | 31 Mar 2025 | $32.3M | $6.1M | $0.02 |
| Q4 FY2024 | 31 Dec 2024 | $30.3M | $43.7M | $0.12 |
| Q3 FY2024 | 30 Sep 2024 | $34.3M | $8.3M | $0.02 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Cannabis flower | $108.5M | 74.0% |
| Cannabis extracts | $37.7M | 25.7% |
| Other | $411.0K | 0.3% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Canada | $90.3M | 61.6% |
| Israel | $41.8M | 28.5% |
| Other countries | $14.5M | 9.9% |
Company events
The newest 8-K filings of 71 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 15 Oct 2026 | 8-K | Deal completed, Material agreement, Investor update | 1.01, 2.01, 7.01, 9.01 |
| 11 Sep 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 7 Aug 2026 | 8-K/A | Shareholder vote | 5.07 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 22 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 11 May 2026 | 8-K | Results, Material agreement, Other events | 1.01, 2.02, 8.01, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 9 Dec 2025 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 29 Aug 2025 | 8-K | Leadership change | 5.02 |
| 7 Aug 2025 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 24 Jun 2025 | 8-K | Shareholder vote | 5.07 |
Every filing
The newest filings with the SEC of 220 held.
| Filed | Form | Period |
|---|---|---|
| 15 Oct 2026 | 8-K | 15 Oct 2026 |
| 11 Sep 2026 | 8-K | 8 Sep 2026 |
| 7 Aug 2026 | 8-K/A | 18 Jun 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 22 Jun 2026 | 8-K | 18 Jun 2026 |
| 29 May 2026 | SD | – |
| 11 May 2026 | 10-Q | 31 Mar 2026 |
| 11 May 2026 | 8-K | 8 May 2026 |
| 24 Apr 2026 | DEFA14A | – |
| 24 Apr 2026 | DEF 14A | 31 Dec 2025 |
| 26 Feb 2026 | 10-K | 31 Dec 2025 |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 12 Feb 2021 | John A. Yarmuth (KY03) | Purchase | $1,001 - $15,000 | 19 Feb 2021 |
| 5 Nov 2020 | John A. Yarmuth (KY03) | Purchase | $1,001 - $15,000 | 15 Nov 2020 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4.0M | +17.53% | 4.75 |
| 30 Sep 2026 | 3.4M | +3.54% | 3.76 |
| 15 Sep 2026 | 3.3M | +0.26% | 4.11 |
| 31 Aug 2026 | 3.2M | -4% | 2.14 |
| 14 Aug 2026 | 3.4M | -1.17% | 1.78 |
| 31 Jul 2026 | 3.4M | -2.23% | 3.95 |
| 15 Jul 2026 | 3.5M | +11.47% | 4.5 |
| 30 Jun 2026 | 3.1M | -14.84% | 3.21 |
Funds that hold it
From each fund's latest Form 13F.
215 funds held it at 30 Jun 2026: 59 added and 42 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| D. E. Shaw & Co., Inc. | 8,840,503 | $24.6M | +1,222,276 |
| Chescapmanager LLC | 7,942,737 | $22.1M | 0 |
| Tidal Investments LLC | 3,767,849 | $10.5M | -259,043 |
| Dimensional Fund Advisors LP | 3,048,254 | $8.5M | +369,203 |
| Mackenzie Financial Corp. | 1,597,039 | $6.3M | +1,597,039 |
| Arrowstreet Capital, Limited Partnership | 1,992,855 | $5.5M | +1,992,855 |
| Renaissance Technologies LLC | 1,742,149 | $4.8M | -267,400 |
| CIBC World Market Inc. | 1,383,299 | $3.8M | +36,479 |
| Mmcap International Inc. SPC | 999,490 | $2.8M | 0 |
| Quinn Opportunity Partners LLC | 969,033 | $2.7M | 0 |
Peers
Companies in the same industry.
- Trulieve Cannabis Corp. (TRLV): revenue $1.1B, market value $2.0B